Venous Thromboembolism - Pipeline Review, H2 2015

Date: November 25, 2015
Pages: 83
Price:
US$ 2,000.00 US$ 1,700.00
Offer valid until December 31, 2016!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: VDD93354F5DEN
Leaflet:

Download PDF Leaflet

Venous Thromboembolism - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Venous Thromboembolism - Pipeline Review, H2 2015’, provides an overview of the Venous Thromboembolism’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Venous Thromboembolism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Venous Thromboembolism and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope
  • The report provides a snapshot of the global therapeutic landscape of Venous Thromboembolism
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Venous Thromboembolism and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Venous Thromboembolism products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Venous Thromboembolism pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Venous Thromboembolism
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Venous Thromboembolism pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Venous Thromboembolism Overview
Therapeutics Development
Pipeline Products for Venous Thromboembolism - Overview
Venous Thromboembolism - Therapeutics under Development by Companies
Venous Thromboembolism - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Venous Thromboembolism - Products under Development by Companies
Venous Thromboembolism - Companies Involved in Therapeutics Development
Bayer AG
Daiichi Sankyo Company, Limited
Gamma Therapeutics, Inc.
GlycoMimetics, Inc.
Green Cross Corporation
Isis Pharmaceuticals, Inc.
Portola Pharmaceuticals, Inc.
Sanofi
Venous Thromboembolism - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles betrixaban - Drug Profile
Product Description
Mechanism of Action
R&D Progress
edoxaban tosylate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gammarin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GCC-2107 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GMI-1271 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ISIS-FXIRx - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Lysimab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
rivaroxaban - Drug Profile
Product Description
Mechanism of Action
R&D Progress
semuloparin sodium - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Venous Thromboembolism - Recent Pipeline Updates
Venous Thromboembolism - Dormant Projects
Venous Thromboembolism - Discontinued Products
Venous Thromboembolism - Product Development Milestones
Featured News & Press Releases
Nov 06, 2015: Bristol-Myers Squibb and Pfizer to Present New Data on Eliquis (apixaban) at the American Heart Association Scientific Sessions 2015
Oct 30, 2015: Portola Pharmaceuticals Completes Enrollment in Pivotal Phase 3 APEX Study of Betrixaban for Prevention of Blood Clots in Acute Medically IllPatients
Oct 30, 2015: Isis Pharmaceuticals Initiates Phase 2 Study of ISIS-FXI Rx in Patients with End-Stage Renal Disease on Hemodialysis
Oct 13, 2015: Portola Pharmaceuticals Announces FDA Grants Fast Track Designation to Betrixaban for Prevention of Blood Clots in Acute Medically Ill Patients
Sep 24, 2015: Bayer’s Xarelto Approved in Japan for the Treatment and Secondary Prevention of Pulmonary Thromboembolism and Deep Vein Thrombosis
Jul 12, 2015: NICE recommends edoxaban tosylate (Lixiana) for treating and preventing potentially fatal blood clots
Jun 18, 2015: Daiichi Sankyo Initiates Hokusai-VTE Cancer Study to Evaluate the Role of Edoxaban in Patients with Venous Thromboembolism Associated with Cancer
Jun 03, 2015: NICE guidance recommends apixaban (Eliquis) for treating and preventing potentially fatal blood clots
Apr 27, 2015: Daiichi Sankyo’s Once-Daily Lixiana (edoxaban) Receives Positive CHMP Opinion for the Prevention of Stroke and Systemic Embolism in Non-Valvular Atrial Fibrillation and for the Treatment and Prevention of Recurrent Venous Thromboembolism in Europe
Apr 15, 2015: Daiichi Sankyo’s Once-Daily Lixiana (edoxaban) Approved for the Prevention of Stroke and Systemic Embolism in Non-Valvular Atrial Fibrillation and for the Treatment and Prevention of Recurrent Venous Thromboembolism in Switzerland
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Venous Thromboembolism, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Products under Development by Companies, H2 2015
Venous Thromboembolism - Pipeline by Bayer AG, H2 2015
Venous Thromboembolism - Pipeline by Daiichi Sankyo Company, Limited, H2 2015
Venous Thromboembolism - Pipeline by Gamma Therapeutics, Inc., H2 2015
Venous Thromboembolism - Pipeline by GlycoMimetics, Inc., H2 2015
Venous Thromboembolism - Pipeline by Green Cross Corporation, H2 2015
Venous Thromboembolism - Pipeline by Isis Pharmaceuticals, Inc., H2 2015
Venous Thromboembolism - Pipeline by Portola Pharmaceuticals, Inc., H2 2015
Venous Thromboembolism - Pipeline by Sanofi, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Venous Thromboembolism Therapeutics - Recent Pipeline Updates, H2 2015
Venous Thromboembolism - Dormant Projects, H2 2015
Venous Thromboembolism - Discontinued Products, H2 2015

LIST OF FIGURES

Number of Products under Development for Venous Thromboembolism, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Targets, H2 2015
Number of Products by Stage and Targets, H2 2015
Number of Products by Mechanism of Actions, H2 2015
Number of Products by Stage and Mechanism of Actions, H2 2015
Number of Products by Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015
Skip to top


Thromboembolism - Pipeline Review, H2 2016 US$ 2,000.00 Jul, 2016 · 101 pages

Ask Your Question

Venous Thromboembolism - Pipeline Review, H2 2015
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: